



Restylane® Skincare - innovative treatment from Q-Med AB

April 8, 2010, Monaco Anti-Aging World Congress

Today Q-Med is pleased to announce a completely new range of products: Restylane® Skincare. Restylane Skincare is a group of high-quality skincare products based on the successful, patented and proven NASHA™ technology. These products will complement the Restylane range of injectable dermal fillers for esthetic treatments.

Restylane Skincare is today being presented at the Anti-Aging World Congress in Monaco. The series of Restylane Skincare products is the result of extensive research and complements the Restylane product portfolio, or can be used as a stand-alone skincare routine.

The secret to beautiful skin is balanced skin hydration combined with a healthy and protective skin barrier. Restylane Skincare combines these two qualities in an innovative series of creams for healthy skincare, which supplements the effect of the injectable Restylane products.

Compared with other skincare products on the market, Restylane Skincare is kind to the natural structure and constitution of the skin. The NASHA gel gives the creams a pleasing consistency, preserves moisture and adds lustre to the skin.

Restylane Skincare consists of six different skincare products: Day Cream, Night Cream, Night Serum, Recover Cream, Hand Cream and Facial Cleanser. The creams will be sold by well-reputed esthetic clinics. The Restylane Skincare series will be available early on in the summer of 2010 in Sweden and other parts of Europe. In Asia Restylane Skincare will be presented at IMCAS in Hong Kong (International Master Course on Aging Skin) from July 10-12, 2010.

“We see great potential in this series of products as it will enhance the effect of our injectable products and tie consumers closer to our partners in between treatments,” says Bengt Ågerup, CEO and founder of Q-Med.

Anna Stinger, Strategic Marketing, continues: “A healthy skin is one of the most desired features when people refer to beauty. This is a natural step for us in our efforts to reach out to our end-consumers and further improve our service to them.”

For more information, please visit: www.q-medpractitioner.com

Read more about the NASHA technology: www.q-med.com

Queries should be addressed to:

Bengt Ågerup, President and CEO

Tel: +46 70 974 9025

Karin Falck, PR & Corporate Communications

Tel: +46 70 974 9015

Anna Stinger, Strategic Marketing

Tel: +46 733 87 15 29

Facts on the NASHA™ gel and hyaluronic acid in general

Hyaluronic acid is one of the few substances that are identical in all living organisms. It is a polysaccharide, a natural sugar, and exists in all the body's organs. Hyaluronic acid is produced by the cells in the human body, where it fills many important functions. It facilitates the cell-division process, makes the skin elastic and lubricates the joints. Hyaluronic acid also has the ability to bind great quantities of water. The properties of natural hyaluronic acid have been much sought after for many years within medical and esthetic applications. But the body's own hyaluronic acid is broken down quickly and must be newly produced constantly. When Q-Med patented the NASHA technology new opportunities therefore opened up. Using the NASHA technology the natural properties of hyaluronic acid can be retained and combined with a long duration in the body. The NASHA process is flexible and from the same base technology Q-Med can produce gels that are adapted to different areas of use, tissues and needs.

Unique properties

None of Q-Med's competitors have managed to manufacture gels of hyaluronic acid with the same ability as the NASHA gels. The least modified competing products are still considerably more chemically changed than the NASHA gels. Competing products are either not as viscous as the NASHA gels, which means that they cannot build and retain volume in the same way, or they are considerably more chemically changed. A great deal of chemical modification means that the material differs to the same extent from natural hyaluronic acid and this may mean that these gels are experienced as substances that are foreign to the body, thus making them less biocompatible.

Q-Med AB is a medical device company that develops, manufactures, markets, and sells high quality medical implants for esthetic and medical use. The majority of the products are based on the company's patented technology, **NASHA™**, for the production of stabilized non-animal hyaluronic acid. The product portfolio today contains: **Restylane®** for filling lines and folds, contouring and creating volume in the face, **Macrolane™** for body contouring, **Durolane™** for the treatment of osteoarthritis of the hip and knee joints, **Deflux®** for the treatment of vesicoureteral reflux, VUR, (a malformation of the urinary bladder) in children, and **Solesta™** for the treatment of fecal incontinence. Sales are made through the company's own subsidiaries or distributors in over 70 countries. Q-Med today has about 650 coworkers, with almost 400 at the company's head office and production facility in Uppsala, Sweden. Q-Med AB is listed in the Mid Cap segment of the NASDAQ OMX Nordic.
